Company / Gross Margin
TherapeuticsMD, Inc. Gross Margin History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
98.0%
FY2023
5-year range
45.5% / 98.0%
FY2019-FY2023
Trend
+115.3%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Margin has fluctuated over the past 9 years, ranging from 45.5% in FY2022 to 98.0% in FY2023.
Based on SEC 10-K filings.
98.0% in FY2023 with a 5-year CAGR of +19.6%.
Improved from 87.2% to 98.0% over the past 2 years.
Gross Margin over time
Growth rates
- 3-Year Change
- +15.0pp
- 5-Year Change
- +19.6pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2023, gross margin increased 115.3% year-over-year.
- Lowest gross margin in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | 98.0% | +115.3% |
| FY2022 | 45.5% | -47.8% |
| FY2021 | 87.2% | +5.1% |
| FY2020 | 83.0% | -1.5% |
| FY2019 | 84.3% | +7.5% |
| FY2018 | 78.4% | +1.0% |
| FY2017 | 77.6% | +2.7% |
| FY2016 | 75.6% | -2.7% |
| FY2015 | 77.7% | +20.1% |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026